Article

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models

2025-07-15

Abstract excerpt

<h4>Background: </h4> CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various approaches, including small molecules, antibodies, and short peptides. Here, we investigated the antitumor effects of the CXCR4 pharmacological inhibition with the synthetic peptides SPX5551 and balixafortid...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3efe3b3b-b5f3-5898-9c27-9265a3a93194
DOI: 10.1101/2025.07.10.664047

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma modelsDOI 10.1101/2025.07.10.664047Read

GPCR Inhibition in Treating LymphomaSemantic proximity Read

A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemiaSemantic proximity Read

Inhibition of BIRC5 and MCL1 as a potential treatment strategy to overcome drug resistance in Mantle Cell LymphomaSemantic proximity Read

The CXCR4-CXCL12-Axis is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects in VitroSemantic proximity Read

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read

At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.Semantic proximity Read

Novel SLAMF1-derived peptide induces apoptosis in multiple myeloma cells by targeting IRF4 transcription factor for degradationSemantic proximity Read

A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphomaSemantic proximity Read

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.Semantic proximity Read

The CD19-4-1BBL antibody fusion protein unleashes the immune system against high-risk chronic lymphocytic leukemiaSemantic proximity Read

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaSemantic proximity Read

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and BeyondSemantic proximity Read